Significant Ownership of AbbVie Inc.

Signature - Title
/s/ Scott T. Reents - Scott T. Reents, Executive Vice President, Chief Financial Officer
Location
North Chicago, IL
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by AbbVie Inc..

Follow Filing Activity

Follow AbbVie Inc. and return when a new Schedule 13D/G filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sponsored

Significant Ownership of AbbVie Inc.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
XLO Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share 9% $3,304,348 4,347,826 AbbVie Inc. 11 Feb 2025

Schedules 13D/G Reported by AbbVie Inc.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.